Hair composition

Patent metadata

Field	Value
Publication number	US-10456344-B2
Application number	US-201515533757-A
Country	US
Kind code	B2
Filing date	Dec 4, 2015
Priority date	Dec 22, 2014
Publication date	Oct 29, 2019
Grant date	Oct 29, 2019

Abstract

Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fiber growth, wherein the oral or topical composition comprises ≤9, preferably ≤8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

First claim

The invention claimed is:

1. An oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth,
wherein the oral or topical composition comprises ≤9% w/w β-sitosterol,
and wherein the nuclear factor erythroid-2 related factor 2 agonist comprises granilin and the liver X receptor agonist comprises a compound selected from the group consisting of 22(R)-hydroxycholesterol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzeneacetic acid hydrochloride (GW 3965) and/or salts thereof, and stigmasterol; or wherein the nuclear factor erythroid-2 related factor 2 agonist comprises 1 μM sulforaphane and the liver X receptor agonist comprises 10 μM 22(R)-hydroxycholesterol, and
wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90% w/w catechins, and
wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, and
wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and
wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

2. An oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic induction of the antioxidant response element and/or up-regulation of hemoxygenase 1 in HaCaT immortalised human keratinocyte cells and/or up-regulation of NAD(P)H dehydrogenase (quinone) 1 in human hair follicle cells,
wherein the oral or topical composition comprises ≤9% w/w β-sitosterol,
and wherein the nuclear factor erythroid-2 related factor 2 agonist comprises granilin and the liver X receptor agonist comprises a compound selected from the group consisting of 22(R)-hydroxycholesterol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzeneacetic acid hydrochloride (GW 3965) and/or salts thereof, and stigmasterol;
or wherein the nuclear factor erythyroid-2 related factor 2 agonist comprises 1 μM sulforaphane and the liver X receptor agonist comprises 10 μM 22(R)-hydroxycholesterol, and
wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90% w/w catechins, and
wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, and
wherein when the oral or topical composition comprises guggelsterone to epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and
wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

3. A method of promoting hair fibre growth comprising applying to hair fibres and/or scalp the oral or topical composition according to claim 1 .

4. A method of inducing antioxidant response element and/or up-regulation of hemoxygenase 1 in HaCaT immortalised human keratinocyte cells and/or up-regulation of NAD(P)H dehydrogenase (quinone) 1 in human hair follicle cells comprising treating the cells with an oral or topical composition according to claim 2 .

5. An oral or topical composition according to claim 1 , wherein the oral or topical composition comprises ≤8% w/w β-sitosterol.

6. An oral or topical composition according to claim 1 , wherein the oral or topical composition comprises 0.005 to 70% w/w catechins.

7. An oral or topical composition according to claim 1 , wherein the oral or topical composition comprises 0.01 to 50% w/w catechins.

8. An oral or topical composition according to claim 2 , wherein the oral or topical composition comprises ≤8% w/w β-sitosterol.

9. An oral or topical composition according to claim 2 , wherein the oral or topical composition comprises 0.005 to 70% w/w catechins.

10. An oral or topical composition according to claim 2 , wherein the oral or topical composition comprises 0.01 to 50% w/w catechins.

Assignees

• Conopco Inc

Inventors

• Bhogal Ranjit Kaur
• Jenkins Gail
• Sawicka Magdalena
• Wainwright Linda Jane

Classifications

• A61P17/14

  for baldness or alopecia · CPC title

• A61K36/68

  Plantaginaceae (Plantain Family) · CPC title

• A61K36/328

  Commiphora, e.g. mecca myrrh or balm of Gilead · CPC title

• A61K36/324

  Boswellia, e.g. frankincense · CPC title

• A61K36/73

  Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn · CPC title